Endobronchial Ultrasound-guided Transbronchial Needle Aspiration for Lymph Node Staging in Patients With Non-small Cell Lung Cancer Pursuing Stereotactic Body Radiotherapy (SBRT)

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

It is reported that more than 90,000 patients died of lung cancer and more than 20% of them were older than 80 years in North America. Therefore a less invasive but effective treatment is required for patients with lung cancer of advanced age, diminished pulmonary functions, and chronic diseases. Stereotactic body radiation therapy (SBRT) is an effective and well-tolerated treatment for early stage lung cancer in medically inoperable patients. On the other hand, accurate mediastinal and hilar lymph node staging is one of the most important factors that determine the outcome and indications for SBRT. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a novel, minimally invasive modality that enables the assessment of mediastinal and hilar lymph nodes with a high sensitivity. Accurate lymph node staging by EBUS-TBNA will allow opportunities for high-risk patients with lung cancer to undergo minimally invasive treatment.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age 18 years or older

• Patients with confirmed lung cancer who require EBUS-TBNA as part of their staging investigations of the mediastinum and hilum prior to SBRT

• Performance status score (WHO/ECOG) of 0-2.

• Cytological or histological proof of non-small cell cancer

• Stage T1-2 disease, with no evidence of distant metastasis

• Patients are screened by both computed tomography (CT) and positron emission tomography (PET)

• Medically inoperable for surgical resection

• Patients who refused surgery

Locations
Other Locations
Canada
Toronto General Hospital
RECRUITING
Toronto
Contact Information
Primary
Judy McConnell
judy.mcconnell@uhn.ca
Time Frame
Start Date: 2013-02
Estimated Completion Date: 2026-12
Participants
Target number of participants: 150
Treatments
Experimental: EBUS-TBNA
Sponsors
Leads: University Health Network, Toronto

This content was sourced from clinicaltrials.gov